In oligoprogressive diseases of ALK+ lung cancer, continuation of ALK TKIs with local ablative therapy should be considered for sustained control, which can potentially eradicate resistant cancer cell clones and confer survival benefit (113). This evidence concerns the gene ALK and cancer.